ST
Silvan Tuerkcan JMP Securities Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
IDEAYA Biosciences
IDYA
$2.26B
| $25.83 | $41 |
59%
upside
| Market Outperform | 16 hours ago |
|
2
Exelixis
EXEL
$10.1B
| $37.38 | $50 |
34%
upside
| Market Outperform | 1 month ago |
|
3
CRISPR Therapeutics
CRSP
$4.8B
| $52.74 | $86 |
63%
upside
| Market Outperform | 2 months ago |
|
4
Nuvation Bio
NUVB
$1.17B
| $3.42 | $6 |
75%
upside
| Market Outperform | 2 months ago |
|
5
Solid Biosciences
SLDB
$433M
| $5.56 | $15 |
170%
upside
| Market Outperform | 3 months ago |
|
6
Taysha Gene Therapies
TSHA
$889M
| $3.26 | $6 |
84%
upside
| Market Outperform | 3 months ago |
|
7
Prime Medicine
PRME
$606M
| $3.40 | $6 |
76%
upside
| Market Outperform | 3 months ago |
|
8
Benitec Biopharma
BNTC
$368M
| $14 | $20 |
43%
upside
| Market Outperform | 3 months ago |
|
9
Foghorn Therapeutics
FHTX
$305M
| $5.39 | $9 |
67%
upside
| Market Outperform | 3 months ago |
|
10
enGene Holdings
ENGN
$256M
| $5 | $18 |
260%
upside
| Market Outperform | 4 months ago |
|
11
Terns Pharmaceuticals
TERN
$618M
| $7.06 | $20 |
183%
upside
| Market Outperform | 4 months ago |
|
|
12
Benitec Biopharma
BNTC
$368M
| $14 | $18 |
29%
upside
| Market Outperform | 5 months ago |
|
|
13
Solid Biosciences
SLDB
$433M
| $5.56 | $15 |
170%
upside
| Market Outperform | 6 months ago |
|
|
14
Prime Medicine
PRME
$606M
| $3.40 | $10 |
194%
upside
| Market Outperform | 6 months ago |
|
15
Relay Therapeutics
RLAY
$690M
| $4 | $21 |
425%
upside
| Market Outperform | 8 months ago |
|
|
CLLS
16
Cellectis
CLLS
$264M
| $2.63 | $6 |
128%
upside
| Market Outperform | 1 year ago |
|
17
monday.com
MNDY
$9.4B
| $182.42 | $280 |
53%
upside
| Buy | 1 year ago |
|
|
TWO
18
Two Harbors Investment
TWO
$1.08B
| $10.40 | $18 |
73%
upside
| Market Outperform | 2 years ago |
|
19
Intellia Therapeutics
NTLA
$1.25B
| $11.62 | $125 |
976%
upside
| Perform | 4 years ago |
|
|
20
Exelixis
EXEL
$10.1B
| $37.38 | $37 |
1%
downside
| Outperform | 5 years ago |
|